Jasper Therapeutics Inc [JSPR] stock is trading at $6.70, up 15.92%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The JSPR shares have gain 14.14% over the last week, with a monthly amount drifted -69.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jasper Therapeutics Inc [NASDAQ: JSPR] stock has seen the most recent analyst activity on December 06, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $63. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 09, 2024, and set its price target to $70. On July 08, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $90 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $86 on June 27, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $65 as its price target on May 06, 2024. Evercore ISI started tracking with a Outperform rating for this stock on April 03, 2024, and assigned it a price target of $65. In a note dated March 28, 2024, RBC Capital Mkts initiated an Outperform rating and provided a target price of $70 on this stock.
Jasper Therapeutics Inc [JSPR] stock has fluctuated between $5.25 and $31.01 over the past year. Currently, Wall Street analysts expect the stock to reach $55.5 within the next 12 months. Jasper Therapeutics Inc [NASDAQ: JSPR] shares were valued at $6.70 at the most recent close of the market. An investor can expect a potential return of 728.36% based on the average JSPR price forecast.
Analyzing the JSPR fundamentals
Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -33.47%, Pretax Profit Margin comes in at -30.96%, and Net Profit Margin reading is -30.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.68 and Total Capital is -0.79. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.01 points at the first support level, and at 5.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.20, and for the 2nd resistance point, it is at 7.70.
Ratios To Look Out For
For context, Jasper Therapeutics Inc’s Current Ratio is 7.61. Also, the Quick Ratio is 7.61, while the Cash Ratio stands at 7.42.
Transactions by insiders
Recent insider trading involved Mahal Jeetinder Singh, Chief Operating Officer, that happened on Dec 12 ’24 when 900.0 shares were sold. Executive Officer, Jeetinder Singh Mahal completed a deal on Dec 12 ’24 to buy 900.0 shares. Meanwhile, Chief Operating Officer Mahal Jeetinder Singh sold 900.0 shares on Sep 12 ’24.
